BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (41)
2023
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294
-
Profiling the immune landscape in mucinous ovarian carcinoma
Gynecologic Oncology, Vol. 168, pp. 23-31
2022
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
2021
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
-
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 2, pp. 97-105
2020
-
Prognostic gene expression signature for high-grade serous ovarian cancer
Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250
2019
-
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
The Lancet, Vol. 393, Núm. 10168, pp. 229-240
-
Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨
Journal of Clinical Oncology
-
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
The Lancet Haematology, Vol. 6, Núm. 2, pp. e67-e78
2018
-
CD34 + Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Biology of Blood and Marrow Transplantation, Vol. 24, Núm. 5, pp. 964-972
-
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204
2017
-
MRD detection in multiple myeloma: Comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods
Blood Advances, Vol. 1, Núm. 12, pp. 728-732
-
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
Cancer Medicine, Vol. 6, Núm. 1, pp. 36-44
-
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
Hematological Oncology
2016
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
-
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346
-
Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)
Annals of Oncology, Vol. 27, pp. vi213
2015
-
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Nature Genetics, Vol. 47, Núm. 2, pp. 164-171
-
Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study
Journal of Clinical Oncology